Rain oncology stock.

NEWARK, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of ...WebRain Oncology, Inc. is a clinical-stage precision oncology company, which focuses on developing and implement the precision oncology therapies for patients suffering from cancer. The company was founded by Avanish Vellanki and Robert Doebele in April 2017 and is headquartered in Newark, CA. Nov 24, 2023 · Company Summary. Rain Oncology Inc. is a late-stage precision oncology company developing therapies which target oncogenic drivers to genetically select patients. The company's lead product ... Rain Oncology (NASDAQ: RAIN) stock is taking a massive beating on Monday after the company revealed its latest clinical trial data. The bad news for investors in RAIN stock is the company’s ...Comprehensive suite of tools for trading and investing in biotech stocks. FDA Calendar, PDUFA Date Calendar, Biotech Company Screener and Database and much more

November 22, 2023. $1.07. 31,967. 1:1. $1.09. $1.09. $1.06. NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits …In the previous week, Rain Oncology had 18 more articles in the media than Celularity. MarketBeat recorded 21 mentions for Rain Oncology and 3 mentions for Celularity. Rain Oncology's average media sentiment score of 0.63 beat Celularity's score of -0.07 indicating that Celularity is being referred to more favorably in the media.WebNov 27, 2023 · Analyst Recommendations on Rain Oncology Inc. Citigroup Trims Rain Oncology's Price Target to $1 From 1.50, Keeps Neutral Rating. Sep. 18. MT. Mizuho Downgrades Rain Oncology to Neutral From Buy, Adjusts Price Target to $1 From $17. Jun. 05. MT. EF Hutton Cuts Rain Oncology's Price Target to $2 From $5, Maintains Hold Rating.

1. Amgen (AMGN) Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. Amgen stock opened the day at $265.12 after a previous close of $264.59.

PFS (Primary): Approximately 105 events by blinded central review to trigger primary analysis. OS, ORR, DCR, DOR. Safety. TP53. Overview. MDM2 gene CN of ≥8. Patients enrolled based on local NGS for CN, centrally confirmed by Rain's diagnostic partner, Tempus. Evaluable tumor types included: lung, breast, biliary, pancreatic and other select ... RAIN Stock 12 Months Forecast. $1.33. (27.88% Upside) Based on 5 Wall Street analysts offering 12 month price targets for Rain Therapeutics in the last 3 months. The average price target is $1.33 with a high forecast of $2.00 and a low forecast of $1.00. The average price target represents a 27.88% change from the last price of $1.04.Insiders who bought Rain Oncology Inc. (NASDAQ:RAIN) stock in the last 12 months were richly rewarded last week. The company's market value increased by US$54m as a result of the stock's 21% gain ...WebThe number of outstanding shares of the company’s common stock is not affected by the name change. The company’s ticker symbol “RAIN” will remain the same. About Rain Oncology.WebNEW YORK, June 21, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Rain Oncology Inc.:. On or around April 22, 2021, Rain conducted its initial public offering ("IPO"), selling more than 7.35 million shares priced at $17.00.

Find the latest Rain Oncology Inc. (RAIN) stock quote, history, news and other vital information to help you with your stock trading and investing. ... RAIN - Rain Oncology Inc. NasdaqGS ...Web

Oct 16, 2023. NEWARK, Calif., October 16, 2023 – Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right (“CVR”) representing the right to receive 80% of the net ...

Rain Oncology stock plummets on late-stage cancer drug results - San Francisco Business Times bizjournals.com 1 Like Comment Share Copy; LinkedIn; Facebook; Twitter; To view ...At Olema Oncology, we leverage our deep understanding of endocrine-driven cancers, nuclear receptors and mechanisms of acquired resistance with the goal of transforming the standard of care for women living with cancer by focusing on developing more convenient and effective therapies. Join us as we aim to design therapies for improving lives.7 brokerages have issued 1 year price targets for ALX Oncology's stock. Their ALXO share price targets range from $10.00 to $34.00. On average, they anticipate the company's stock price to reach $20.42 in the next year. This suggests a possible upside of 154.9% from the stock's current price. View analysts price targets for ALXO or view …About Rain Oncology Inc. Rain Oncology Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology.

Nov 04, 2022. NEWARK, Calif., November 4, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the pricing of a registered offering of 6,861,080 shares of common stock and 1,715,250 shares of non-voting …WebAbout Clovis Oncology Stock (NASDAQ:CLVSQ) Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose …Cardiff Oncology stock price target cut to $14 from $25 at Maxim Group. Jan. 24, 2022 at 7:47 a.m. ET by Tomi Kilgore. Cardiff Oncology stock price target raised to $25 from $20 at Maxim Group.NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the ...May 12, 2023 · Rain Therapeutics (RAIN) LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Rain Therapeutics today and set a price target of $17.00 . The company’s shares closed last Thursday at $9.28.

Why Shares of Rain Oncology Are Plummeting Today. Shares of Rain Oncology (NASDAQ: RAIN) were down 87% Monday afternoon after the precision oncology company released top-line results for its lead ...

Find the latest Rain Oncology Inc. (RAIN) stock quote, history, news and other vital information to help you with your stock trading and investing.Rain Oncology ( NASDAQ: RAIN) fell ~81% in the pre-market Monday after announcing that its lead product candidate, milademetan, did not reach the primary endpoint in a Phase 3 trial for patients ...A high-level overview of ALX Oncology Holdings Inc. (ALXO) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Rain Therapeutics. NEWARK, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”) (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology ...WebRain Oncology Inc (RAIN) stock is down -87.44% while the S&P 500 has risen 0.1% as of 11:09 AM on Monday, May 22. RAIN is down -$8.68 from the previous closing price of $9.93 on volume of 16,197,454 shares. Over the past year the S&P 500 is higher by 5.60% while RAIN is down -51.92%. RAIN lost -$2.61 per share in the over the last 12 months.Stockholder / Stock options: Rain Therapeutics; Advisory / Consultancy: Chair of Scientific Advisory. Board for Rain Therapeutics; Honoraria (self): Guardant ...Stock analysis for Rain Oncology Inc (RAIN:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.WebNovember 22, 2023. $1.07. 31,967. 1:1. $1.09. $1.09. $1.06. NOTE: The Closing Price, Day's High, Day's Low, and Day's Volume have been adjusted to account for any stock splits …About Rain Oncology Inc. Rain Oncology Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology.Rain Oncology Inc. is a late-stage precision oncology company. The Company is focused on developing therapies that target oncogenic drivers to genetically select patients. Its product candidate includes milademetan.

NEWARK, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”) (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that it will change its name to Rain Oncology Inc. effective ...

Company Overview. Rain Oncology is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than ...

Rain Oncology Confirms Receipt of Unsolicited Proposal from Concentra Biosciences. NEWARK, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra Biosciences LLC to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a ...Apr 18, 2023 · Rain Oncology Inc (RAIN) stock is trading at $7.36 as of 1:33 PM on Tuesday, Apr 18, a loss of -$0.08, or -1.08% from the previous closing price of $7.44. The stock has traded between $7.20 and $7.45 so far today. Volume today is less active than usual. Stocks / Pharmaceuticals & Biotech RAIN Rain Oncology NasdaqGS:RAIN Stock Report Add to watchlist Add to portfolio Last Price US$1.07 Market Cap …Stock Price Forecast The 4 analysts offering 12-month price forecasts for Rain Oncology Inc have a median target of 1.38, with a high estimate of 2.00 and a low estimate of 1.00. NEWARK, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (Rain), a late-stage biotechnology company developing precision oncology therapeutics, today announced the pricing of a registered offering of 6,861,080 shares of common stock and 1,715,250 shares of non-voting common stock. The …WebComing off stock drops following safety concerns over its recently approved eye injection Syfovre--which turned out to be related to the needle used to deliver the medicine, ... Rain Oncology is laying off 65% of its staff, including its chief medical officer. This news came one week after the company's lead candidate, ...Rain Oncology ( NASDAQ: RAIN) fell ~81% in the pre-market Monday after announcing that its lead product candidate, milademetan, did not reach the primary endpoint in a Phase 3 trial for patients ...On average, Wall Street analysts predict that Rain Oncology's share price could fall to $1.00 by Sep 18, 2024. The average Rain Oncology stock price prediction ...With the company starting 2023 with 8,725 employees, that’s an 11.5% workforce reduction. Story. July 24 - Heron Therapeutics: Heron is turning to layoffs for the second time in 13 months to cut ...Nov 22, 2023 · The company's lead product candidate is milademetan, a small molecule oral inhibitor of MDM2-p53 complex that reactivates p53. The company was formerly known as Rain Therapeutics Inc. and changed its name to Rain Oncology Inc. in December 2022. Rain Oncology Inc. was incorporated in 2017 and is headquartered in Newark, California.

12 brokers have issued 12-month price objectives for Rain Oncology's stock. Their RAIN share price targets range from $11.00 to $24.00. On average, they anticipate …Nanopore design. The concept of nanopore sequencing emerged in the 1980s and was realized through a series of technical advances in both the nanopore and the associated motor protein 1,4,5,6,7,8 ...Find the latest Pyxis Oncology, Inc. (PYXS) stock quote, history, news and other vital information to help you with your stock trading and investing.View the latest Oncology Pharma Inc. (ONPH) stock price, news, historical charts, analyst ratings and financial information from WSJ.Instagram:https://instagram. fastest futures trading platformfed inflationhow to buy amc stockbest mid cap value etf Events. News & press releases. Investors. Overview. Stock Information. Analyst Coverage. Stock Quote & Chart. Historical Price Lookup. Investment Calculator. hardest golf course in usahighest rated 529 plans 7 Sept 2023 ... SHAREHOLDER ALERT: Levi & Korsinsky Notifies Rain Oncology Inc.(RAIN) Investors of a Class Action Lawsuit and Upcoming Deadline. Levi & ...Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you. stocks with the highest short interest 31 May 2023 ... Rain plans to continue evaluating the Phase 3 MANTRA data and present those findings at a medical conference later in the year. The company also ...Which Rain Oncology insiders have been buying company stock? The following insiders have purchased RAIN shares in the last 24 months: Aaron I Davis ($5,667,995.96), Bvf Partners L P/Il ($9,971,387.14), Franklin M Berger ($351,000.00), and Kevin C Tang ($1,179,304.12).Web